HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Skin care trends

This article was originally published in The Rose Sheet

Executive Summary

Traditional skin care marketers are attempting to compete with dermatologist-developed skin care brands such as Dr. Perricone and Dr. Brandt by offering products with therapeutic, high-end positioning, market research firm Kline & Co. concludes in skin care study to be published this fall. Products pursuing that approach include Avon Clinical and P&G's Olay Regenerist, which are touted as advanced anti-aging offerings. Prestige marketers such as Estee Lauder also are offering more clinically-positioned skin care treatments. Lauder recently purchased dermatologist-developed Rodan & Field's skin care line, while firm's Prescriptives brand relies on spokesperson Dr. Karen Grossman to promote its Dermapolish at-home microdermabrasion system (1"The Rose Sheet" July 21, 2003, p. 9)...

You may also be interested in...



Lauder Rodan & Fields Buy Adds Dermatological Brand To Skin Care Portfolio

Estee Lauder is moving into the dermatological skin care category with the acquisition of Rodan & Fields, a product line developed by dermatologists and sold in selective high-end department stores

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel